Eribulin mesylate for the treatment of breast cancer

By Cigler Tessa   Vahdat Linda T  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 9, 2010-06 ,pp. : 1587-1593

Informa Healthcare

Access to resources Recommend Favorite

A letter clarifying the way the strength of Halaven (eribulin) is expressed in the product information

By  

Reactions Weekly, Vol. 1, Iss. 1390, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer

By O'Sullivan Coyne Geraldine   Walsh Janice   Kelly Catherine M  

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 643-650

Informa Healthcare

Access to resources Recommend Favorite

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 386-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 374-385

John Wiley & Sons Inc

Access to resources Recommend Favorite